Zhejiang Dayang Biology Technology Co.,Ltd.
SZSE:003017.SZ
30.6 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 919.451 | 1,058.105 | 783.209 | 678.335 | 621.751 | 584.159 | 554.719 | 441.234 | 448.099 | 458.566 | 499.725 |
| Cost of Revenue
| 753.176 | 911.85 | 631.046 | 512.648 | 465.492 | 433.763 | 416.087 | 335.924 | 350.157 | 364.723 | 392.358 |
| Gross Profit
| 166.276 | 146.255 | 152.163 | 165.687 | 156.258 | 150.396 | 138.633 | 105.31 | 97.942 | 93.842 | 107.367 |
| Gross Profit Ratio
| 0.181 | 0.138 | 0.194 | 0.244 | 0.251 | 0.257 | 0.25 | 0.239 | 0.219 | 0.205 | 0.215 |
| Reseach & Development Expenses
| 39.215 | 34.062 | 27.837 | 22.33 | 20.479 | 18.231 | 39.263 | 35.4 | 0 | 18.688 | 14.776 |
| General & Administrative Expenses
| 16.81 | 13.544 | 16.215 | 15.164 | 11.491 | 13.886 | -33.108 | -0.9 | 58.644 | 49.831 | 47.743 |
| Selling & Marketing Expenses
| 9.822 | 8.831 | 7.469 | 7.279 | 21.667 | 20.934 | 20.327 | 17.405 | 13.134 | 17.666 | 17.486 |
| SG&A
| 26.631 | 22.376 | 23.684 | 22.443 | 33.158 | 34.82 | -12.781 | 16.504 | 71.778 | 71.954 | 67.964 |
| Other Expenses
| -9.305 | 33.137 | 27.295 | 16.74 | 14.338 | -3.596 | 4.568 | 14.139 | 0 | 0 | 0 |
| Operating Expenses
| 103.573 | 89.574 | 78.816 | 61.513 | 67.976 | 67.934 | 69.351 | 79.33 | 73.672 | 57.416 | 71.136 |
| Operating Income
| 56.292 | 59.194 | 79.326 | 101.711 | 87.104 | 78.746 | 57.556 | 17.374 | 23.823 | 17.682 | 33.862 |
| Operating Income Ratio
| 0.061 | 0.056 | 0.101 | 0.15 | 0.14 | 0.135 | 0.104 | 0.039 | 0.053 | 0.039 | 0.068 |
| Total Other Income Expenses Net
| -9.305 | -1.739 | -3.187 | -1.451 | -0.376 | -7.312 | -13.911 | 5.063 | 0.447 | 10.959 | -6.579 |
| Income Before Tax
| 46.987 | 57.455 | 76.138 | 100.26 | 86.728 | 75.151 | 55.371 | 31.044 | 24.27 | 28.641 | 27.282 |
| Income Before Tax Ratio
| 0.051 | 0.054 | 0.097 | 0.148 | 0.139 | 0.129 | 0.1 | 0.07 | 0.054 | 0.062 | 0.055 |
| Income Tax Expense
| -3.02 | -23.272 | 6.129 | 8.654 | 7.231 | 4.354 | 5.119 | 2.189 | 0.605 | 0.566 | 0.99 |
| Net Income
| 50.007 | 80.727 | 70.009 | 91.606 | 79.497 | 70.797 | 50.256 | 28.815 | 23.666 | 28.072 | 26.322 |
| Net Income Ratio
| 0.054 | 0.076 | 0.089 | 0.135 | 0.128 | 0.121 | 0.091 | 0.065 | 0.053 | 0.061 | 0.053 |
| EPS
| 0.62 | 0.99 | 0.83 | 1.09 | 0.95 | 1.69 | 1.3 | 0.86 | 0.72 | 0.61 | 0.57 |
| EPS Diluted
| 0.62 | 0.99 | 0.83 | 1.09 | 0.95 | 1.69 | 1.3 | 0.86 | 0.72 | 0.61 | 0.57 |
| EBITDA
| 134.458 | 120.874 | 126.433 | 132.064 | 117.817 | 104.871 | 92.195 | 63.807 | 45.304 | 37.812 | 53.661 |
| EBITDA Ratio
| 0.146 | 0.114 | 0.161 | 0.195 | 0.189 | 0.18 | 0.166 | 0.145 | 0.101 | 0.082 | 0.107 |